EXELIXIS
SpecialtyEXELIXIS is a specialty pharmaceutical company focused on Oncology, Metabolic, Gastroenterology. Key products include CABOMETYX.
EXELIXIS at a Glance
- Growing R&D activity with 8 trials in last 2 years
Upcoming FDA Decisions
Full Calendar →EXELIXIS's Key Drugs
EXELIXIS's core commercial portfolio centers on CABOMETYX, COMETRIQ, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
EXELIXIS's Recent FDA Approvals
New NDA/BLA approvals for EXELIXIS over the last two years — novel drugs only, excluding generics and label supplements.
EXELIXIS's Therapeutic Areas
EXELIXIS's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EXELIXIS's Top Competitors
EXELIXIS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Takeda, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EXELIXIS Pipeline Snapshot
EXELIXIS has 45 active clinical programs from ClinicalTrials.gov — 15 Phase 3, 5 Phase 2 and 25 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/11 completed
- • Speed: 41 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges